Evolent Health, Inc. announced on August 18, 2025, its intention to offer $140.0 million in aggregate principal amount of convertible senior notes due 2031. Additionally, the company plans to grant initial purchasers an option to buy up to an additional $20.0 million in notes. The notes are aimed at qualified institutional buyers under Rule 144A of the Securities Act of 1933. Evolent intends to use up to $100.0 million of the net proceeds to repurchase a portion of its 1.50% convertible senior notes due 2025, and approximately $40.0 million to repurchase shares of its Class A common stock. The notes and any Class A common stock issuable upon conversion are not registered under the Securities Act or any state securities laws.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。